Truist Financial Corp Sells 4,250 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Truist Financial Corp decreased its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.4% in the fourth quarter, HoldingsChannel reports. The fund owned 29,942 shares of the medical research company’s stock after selling 4,250 shares during the quarter. Truist Financial Corp’s holdings in Charles River Laboratories International were worth $5,527,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of CRL. Versant Capital Management Inc grew its position in shares of Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 150 shares during the period. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after buying an additional 65 shares in the last quarter. Assetmark Inc. lifted its stake in shares of Charles River Laboratories International by 1,153.3% during the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International during the 3rd quarter valued at $59,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CRL shares. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Bank of America lowered their target price on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. TD Cowen lifted their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, Barclays lowered their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has a consensus rating of “Hold” and an average price target of $195.71.

Insider Transactions at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $163.11 on Friday. The company’s 50-day moving average price is $172.84 and its 200-day moving average price is $188.09. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The company has a market cap of $8.34 billion, a PE ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the firm posted $2.46 EPS. The business’s quarterly revenue was down 1.1% on a year-over-year basis. On average, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).